NasdaqGS - Delayed Quote • USD
Insmed Incorporated (INSM)
At close: April 25 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 15 | 15 | 16 |
| Avg. Estimate | -1.23 | -1.14 | -4.6 | -3.82 |
| Low Estimate | -1.38 | -1.42 | -5.26 | -5.57 |
| High Estimate | -1.11 | -0.9 | -3.71 | -2.87 |
| Year Ago EPS | -1.17 | -1.78 | -5.34 | -4.6 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 15 | 16 |
| Avg. Estimate | 78.58M | 88.37M | 355.67M | 515.48M |
| Low Estimate | 73.7M | 84.9M | 343.7M | 422.99M |
| High Estimate | 86.2M | 92.44M | 377.25M | 615M |
| Year Ago Sales | 64.51M | 77.23M | 305.21M | 355.67M |
| Sales Growth (year/est) | 21.80% | 14.40% | 16.50% | 44.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.11 | -1.13 | -1.13 | -1.15 |
| EPS Actual | -1.17 | -1.78 | -1.11 | -1.28 |
| Difference | -0.06 | -0.65 | 0.02 | -0.13 |
| Surprise % | -5.40% | -57.50% | 1.80% | -11.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -1.23 | -1.14 | -4.6 | -3.82 |
| 7 Days Ago | -1.23 | -1.13 | -4.6 | -3.8 |
| 30 Days Ago | -1.23 | -1.13 | -4.6 | -3.8 |
| 60 Days Ago | -1.21 | -1.13 | -4.54 | -3.43 |
| 90 Days Ago | -1.16 | -1.14 | -4.49 | -3.44 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | INSM | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -5.10% | -- | -- | 2.60% |
| Next Qtr. | 36.00% | -- | -- | 13.40% |
| Current Year | 13.90% | -- | -- | 5.20% |
| Next Year | 17.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Initiated | Truist Securities: Buy | 4/23/2024 |
| Maintains | Barclays: Overweight to Overweight | 4/11/2024 |
| Maintains | Wells Fargo: Overweight to Overweight | 4/1/2024 |
| Maintains | Guggenheim: Buy to Buy | 2/27/2024 |
| Initiated | UBS: Buy | 2/27/2024 |
| Initiated | Wolfe Research: Outperform | 2/15/2024 |
Related Tickers
SWTX SpringWorks Therapeutics, Inc.
44.20
+1.89%
RARE Ultragenyx Pharmaceutical Inc.
43.85
-0.97%
MRUS Merus N.V.
44.93
+7.05%
FOLD Amicus Therapeutics, Inc.
10.17
-3.51%
IMVT Immunovant, Inc.
27.75
-3.65%
TVTX Travere Therapeutics, Inc.
5.39
-1.10%
KRYS Krystal Biotech, Inc.
155.68
-2.12%
PRAX Praxis Precision Medicines, Inc.
52.88
+3.40%
MLTX MoonLake Immunotherapeutics
42.25
-0.42%
IMCR Immunocore Holdings plc
58.00
-0.80%